Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yali Fu

Showing results (61-70 of 62) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 62 results.
The New England Journal of Medicine|April 17, 2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenMatthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Cancer Research Communications|October 30, 2025
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid TumorsKristoffer Staal Rohrberg, Juanita S Lopez, Mohammed M Milhem, et al.
Pageof 7

Showing results (61-70 of 62) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 62 results.
The New England Journal of Medicine|April 17, 2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenMatthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Cancer Research Communications|October 30, 2025
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid TumorsKristoffer Staal Rohrberg, Juanita S Lopez, Mohammed M Milhem, et al.
Pageof 7